- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946497
CAPN12 Gene Expression as a Molecular Discriminator
CAPN12 Gene Expression as a Molecular Discriminator Between Methotrexate Treated Chronic Plaque Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.
Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.
Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.
CAPN12 is a calcium-dependent cysteine protease expressed in the epidermis and hair follicles and implicated in skin barrier biology and keratinocyte differentiation. Recent integrative single-cell RNA sequencing and Mendelian randomization work identified CAPN12 among genetically informed psoriasis related candidate genes and linked it to increased psoriasis susceptibility.
The same work reported that these candidate genes were predominantly expressed in CD4+ T cells, supporting the feasibility of peripheral blood mononuclear cell-based expression assessment .
Because methotrexate can modulate immune-cell activity, this study will restrict patient recruitment to methotrexate-treated patients on a stable regimen. This design aims to explore whether CAPN12 expression can discriminate between methotrexate-treated cutaneous-only psoriasis and methotrexate-treated psoriatic arthritis, and whether CAPN12 expression correlates with clinical activity indices.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Sherine Adly Hashem, MSc
- Phone Number: +201011000258
- Email: Sherry.adly.7@gmail.com
Study Contact Backup
- Name: Soheir Abdel Hamid Ali, M.D
- Phone Number: +201066877345
- Email: Soher.abdelhamed@med.svu.edu.eg
Study Locations
-
-
-
Qina, Egypt
- Recruiting
- South Valley University Hospital
-
Contact:
- Mohamed Hosney Hassan, Professor
- Phone Number: +201006393764
- Email: mohammedhosneyhassan@med.svu.edu.eg
-
Contact:
- Amr Mohamed Alnoby Aldowy, Lecturer
- Phone Number: +201017789975
- Email: Amrnoby1990@gmail.com
-
Sub-Investigator:
- Shimaa Saber Ahmed, M.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Type of the study: Case-control molecular study.
- Study Setting: Qena University Hospital, Department of Dermatology, Venereology& Andrology and Rheumatology Clinics.
- Study subjects: This study will include adult participants recruited from the outpatient Dermatology and Rheumatology Clinics.
- Receiver operating characteristic curve analysis will be used to evaluate the diagnostic performance of CAPN12 expression.
- Multivariate logistic regression may be performed to test whether CAPN12 expression is independently associated with psoriatic arthritis status.
Description
Inclusion Criteria:
- Patients aged 18 -70 years.
- The severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity).
- Confirmed diagnosis: Psoriasis vulgaris (PsV) or Psoriatic arthritis (PsA) diagnosed by a dermatologist/rheumatologist.
- Willingness to participate: Signed informed consent.
- Patients on stable dose of methotrexate (MTX) therapy.
- Availability for follow-up: Patients must be willing and able to attend scheduled visit.
Exclusion Criteria:
- Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Pregnancy and lactation.
- Patients currently undergoing immunosuppressive or systemic therapies.
- Patients with known genetic disorders affect immune system function.
- Patients with liver or kidney impairment.
- Patients with allergy or contraindication to methotrexate.
- Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
- Previous genetic analysis: Patients who have previously undergone genetic analysis for the CAPN12 gene expression.
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Chronic plaque psoriasis group
About 35 patients suffering from chronic plaque psoriasis and clinically diagnosed chronic plaque psoriasis receiving a stable methotrexate regimen for at least 12 weeks, with no clinical evidence of psoriatic arthritis.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
Other Names:
|
|
Psoriatic arthritis group
About 35 patients suffering from Psoriatic arthritis and diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) and receiving a stable methotrexate regimen for at least 12 weeks.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
Other Names:
|
|
Healthy Control group
About 35 participants inwhich age- and sex-matched apparently healthy individuals with no history of psoriasis, psoriatic arthritis, other autoimmune or chronic inflammatory diseases, and no history of methotrexate therapy. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CAPN12 mRNA expression
Time Frame: 3 Months
|
Assessment of the Difference in relative CAPN12 mRNA expression among the three studied groups. |
3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Relief
Time Frame: 3 Months
|
Assessment of the patients of the study from the pain after treatment using Visual Analogue Scale (VAS) where as 0 for none up to 10 for very severe |
3 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Eisa Mohammed Hegazy, M.D, Professor of Dermatology,Venereology and Andrology,Faculty of Medicine
- Study Director: Marwa Alyan Abdelaziz Mohammed, M.D, Lecturer of Dermatology,Venereology and Andrology,Faculty of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Arthritis
- Joint Diseases
- Spinal Diseases
- Spondylarthropathies
- Skin Diseases, Papulosquamous
- Skin Diseases
- Spondylarthritis
- Spondylitis
- Psoriasis
- Skin and Connective Tissue Diseases
- Arthritis, Psoriatic
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Pterins
- Pteridines
- Aminopterin
- Methotrexate
Other Study ID Numbers
- CAPN12 Gene Expression
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.